TTY BIOPHARM COMPANY LIMITED Toevoegen aan een lijst
|
slotkoers
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
| 78,4 TWD | +0,51% |
|
+1,03% | -2,49% |
Totale waarde
| Fiscaal tijdperk: december | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Marktkapitalisatie 1 | 20.489 | 17.057 | 17.107 | 20.737 | 19.991 | 19.494 | - |
| Bedrijfswaarde 1 | 19.644 | 16.961 | 16.600 | 20.737 | 19.991 | 19.494 | 19.494 |
| K/w-verhouding | 22,8 x | 18,5 x | 20,6 x | 19 x | 17,7 x | 14,5 x | 11,8 x |
| Dividendrendement | 4,85% | 5,83% | 4,36% | 4,08% | 4,35% | - | - |
| Marktkapitalisatie/omzet | 4,59 x | 4,04 x | 3,77 x | 4,1 x | 3,63 x | 3,36 x | 3,09 x |
| Bedrijfswaarde/omzet | 4,59 x | 4,04 x | 3,77 x | 4,1 x | 3,63 x | 3,36 x | 3,09 x |
| Bedrijfswaarde/EBITDA | 14,8 x | 15,3 x | 13,1 x | 14,7 x | 12,7 x | 10,4 x | 9,73 x |
| Bedrijfswaarde/FCF | 17,6 x | 47,6 x | 14,3 x | 18,1 x | 19,7 x | 17,8 x | - |
| FCF Yield | 5,67% | 2,1% | 6,99% | 5,52% | 5,07% | 5,63% | - |
| Price to Book | 3,68 x | 3,13 x | 3,31 x | 3,66 x | 3,36 x | 2,99 x | - |
| Aantal aandelen (in duizenden) | 248.650 | 248.650 | 248.650 | 248.650 | 248.650 | 248.650 | - |
| Referentieprijs 2 | 82,40 | 68,60 | 68,80 | 83,40 | 80,40 | 78,40 | 78,40 |
| Datum van publicatie | 15-03-20 | 19-03-21 | 09-03-22 | 14-03-23 | 14-03-24 | - | - |
1TWD in Miljoen2TWD
Geschatte gegevens
Evolutie van de resultatenrekening (Jaargegevens)
| Fiscaal tijdperk: december | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Omzet 1 | 4.466 | 4.222 | 4.536 | 5.062 | 5.506 | 5.798 | 6.303 |
| EBITDA 1 | 1.381 | 1.114 | 1.308 | 1.414 | 1.573 | 1.872 | 2.003 |
| Bedrijfsresultaat (EBIT) 1 | 1.229 | 957,4 | 1.141 | 1.228 | 1.372 | 1.616 | 1.918 |
| Operationele Marge | 27,51% | 22,68% | 25,15% | 24,26% | 24,93% | 27,88% | 30,43% |
| Resultaat voor belastingen (EBT) 1 | 1.203 | 1.202 | 1.087 | 1.408 | 1.419 | 1.706 | 2.122 |
| Nettowinst (verlies) 1 | 900,1 | 924,2 | 831,9 | 1.094 | 1.129 | 1.346 | 1.659 |
| Nettomarge | 20,15% | 21,89% | 18,34% | 21,62% | 20,5% | 23,22% | 26,32% |
| WPA 2 | 3,610 | 3,710 | 3,340 | 4,400 | 4,530 | 5,415 | 6,670 |
| Free Cash Flow 1 | 1.162 | 358,2 | 1.196 | 1.144 | 1.014 | 1.097 | - |
| FCF-marge | 26,01% | 8,49% | 26,37% | 22,61% | 18,42% | 18,92% | - |
| Kasstroomconversie (ebitda) | 84,12% | 32,15% | 91,44% | 80,91% | 64,45% | 58,6% | - |
| Kasstroomconversie (nettowinst) | 129,06% | 38,76% | 143,77% | 104,55% | 89,85% | 81,47% | - |
| Dividend per aandeel | 4,000 | 4,000 | 3,000 | 3,400 | 3,500 | - | - |
| Datum van publicatie | 15-03-20 | 19-03-21 | 09-03-22 | 14-03-23 | 14-03-24 | - | - |
1TWD in Miljoen2TWD
Geschatte gegevens
Evolutie van de resultatenrekening (Kwartaalgegevens)
| Fiscaal tijdperk: december | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Omzet 1 | 1.468 | 1.037 | 1.166 | 1.326 | 1.533 | 1.166 | 1.262 | 1.433 | 1.645 | 1.274 | 1.353 | 1.563 | 1.796 | 1.306 |
| EBITDA | 420,3 | 291,6 | 343 | 414,5 | 365,2 | 295,4 | - | - | - | - | - | - | - | - |
| Bedrijfsresultaat (EBIT) 1 | 376,8 | 246,6 | 297,7 | 369 | 314,7 | 245,4 | 334 | 504,4 | 288,6 | 309,9 | 365 | 512 | 557 | 302 |
| Operationele Marge | 25,66% | 23,77% | 25,54% | 27,83% | 20,53% | 21,04% | 26,47% | 35,2% | 17,55% | 24,33% | 26,98% | 32,76% | 31,01% | 23,12% |
| Resultaat voor belastingen (EBT) 1 | 425,6 | 287,2 | 351 | 437 | 333,1 | 293,3 | 393,4 | 505,7 | 227 | 368,1 | 402 | 568 | 593 | 337 |
| Nettowinst (verlies) 1 | 343,5 | 227,5 | 284,2 | 338 | 244,7 | 238,7 | 308,7 | 376,3 | 204,8 | 280,8 | 316 | 449 | 452 | 271 |
| Nettomarge | 23,39% | 21,94% | 24,38% | 25,49% | 15,96% | 20,46% | 24,47% | 26,26% | 12,45% | 22,05% | 23,36% | 28,73% | 25,17% | 20,75% |
| WPA 2 | 1,380 | 0,9100 | 1,140 | 1,360 | 0,9900 | 0,9600 | 1,240 | 1,510 | 0,8200 | 1,130 | 1,270 | 1,810 | 1,820 | 1,090 |
| Dividend per aandeel | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Datum van publicatie | 09-03-22 | 13-05-22 | 05-08-22 | 04-11-22 | 14-03-23 | 11-05-23 | 10-08-23 | 03-11-23 | 14-03-24 | 10-05-24 | - | - | - | - |
1TWD in Miljoen2TWD
Geschatte gegevens
Balans
| Fiscaal tijdperk: december | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Nettoschuldpositie | - | - | - | - | - | - | - |
| Nettokaspositie | 845 | 96,6 | 507 | - | - | - | - |
| Hefboom (schuld/ebitda) | - | - | - | - | - | - | - |
| Free Cash Flow 1 | 1.162 | 358 | 1.196 | 1.144 | 1.014 | 1.097 | - |
| ROE (netto-inkomsten/eigen vermogen) | 15,8% | 16,8% | 15,7% | 20,2% | 19,5% | 19,2% | 20,8% |
| ROA (netto-inkomsten/totale activa) | 9,68% | 9,77% | 8,92% | 11,6% | 11,6% | 12,8% | 13,6% |
| Totale activa 1 | 9.303 | 9.457 | 9.329 | 9.449 | 9.738 | 10.515 | 12.190 |
| Nettoactief per aandeel 2 | 22,40 | 21,90 | 20,80 | 22,80 | 23,90 | 26,20 | - |
| Cashflow per aandeel | 4,860 | 2,110 | 5,040 | 4,970 | - | - | - |
| Capex 1 | 48,2 | 168 | 60,3 | 91,5 | 71,3 | 72 | 75 |
| Capex/omzet | 1,08% | 3,98% | 1,33% | 1,81% | 1,3% | 1,24% | 1,19% |
| Datum van publicatie | 15-03-20 | 19-03-21 | 09-03-22 | 14-03-23 | 14-03-24 | - | - |
1TWD in Miljoen2TWD
Geschatte gegevens
WPA & Dividend
Historische koers/winstverhouding
Historische marktkapitalisatie/EBITDA
Trading rating
Beleggingsrating
ESG Refinitiv
Verkoop
Koop
Gemiddeld advies
Houden
Aantal analisten
3
Laatste slotkoers
78,4
TWD
Gemiddelde koersdoel
86,5
TWD
Spread / Gemiddelde doel
+10,33%
Herzieningen van WPA
| Vaira. 1 jan. | Kapi. | |
|---|---|---|
| -2,49% | 601 mln. | |
| +30,38% | 684 mld. | |
| +26,51% | 568 mld. | |
| -4,36% | 361 mld. | |
| +19,30% | 329 mld. | |
| +3,73% | 284 mld. | |
| +16,70% | 240 mld. | |
| +8,78% | 208 mld. | |
| -7,93% | 200 mld. | |
| +7,68% | 166 mld. |
- Beurs
- Aandelen
- Koers 4105
- Financiën TTY Biopharm Company Limited
